Observational studyBMC nephrology2025
Homocysteine levels alter the TyG index-CKD link in Chinese hypertensive patients.
Observational study in BMC nephrology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND AND
aimsHomocysteine (Hcy) is an established non-traditional risk factor for chronic kidney disease (CKD). However, the association between the triglyceride-glucose (TyG) index and CKD, and how this association may be modified by Hcy levels, remains unclear. This study aimed to investigate whether the association between the TyG index and CKD in hypertensive patients is modified by Hcy levels and to examine this potential interaction. METHODS AND
results26679 subjects were included in this multicenter observational study. The TyG index was calculated as ln [TG (mg/dL) × fasting triglycerides (mg/dL)/2]. CKD was defined as an estimated glomerular filtration rate (eGFR) < 60 ml/min/1.73 m2. The association between the TyG index and CKD was analyzed using fitted smoothing curves and multivariable logistic regression. The overall prevalence of CKD was 7.0%. The association between the TyG index and CKD was modified by Hcy levels. A significant positive association was observed in participants with Hcy > 15 μmol/L (ORs per 1-unit increase: 1.37; 95% CI: 1.22, 1.54), but not in those with Hcy ≤15 μmol/L (ORs: 1.33; 95% CI: 0.99, 1.78). In quartile analyses, the association was stronger in the Hcy > 15 μmol/L group, with ORs (95% CI) of 1.38 (1.17, 1.63), 1.46 (1.22, 1.75), and 1.67 (1.37, 2.05) for Q2–Q4, respectively. In the Hcy ≤15 μmol/L group, the corresponding ORs were 1.38 (0.88, 2.15), 1.35 (0.84, 2.15), and 1.80 (1.09, 2.97). Moreover, after adjusting for confounding factors, a significant synergistic effect of high TyG index and Hcy on CKD risk was observed (OR = 11.47; 95% CI: 7.91, 16.65).
conclusionOur study findings suggest that Hcy and the TyG index are independently associated with an increased risk of CKD among Chinese patients with hypertension. The TyG index was strongly and consistently associated with increased CKD risk in individuals with elevated Hcy (>15 μmol/L), but this association was attenuated in those with lower Hcy levels.
trial registrationThe China H-type Hypertension Registry Study (CHHRS) was registered in ChiCTR1800017274 on. July 20, 2018.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.